Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind placebo-controlled study of namodenoson for nonalcoholic steatohepatitis
MOH_2021-06-09_010035Phase 2Not yet recruiting
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Namodenoson with Placebo (2 arms). Primary endpoints: Histologic improvement in NAS and Safety profile of namodenoson. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
namodenoson
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on MOH_2021-06-09_010035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-06-09_010035.